Home » News: Workers Seek to Hold Bayer Accountable in Berkeley
News: Workers Seek to Hold Bayer Accountable in Berkeley
International Longshore and Warehouse Union
BERKELEY, CA--Four-hundred workers at the Bayer Pharmaceutical plant in Berkeley, California are asking the company to honor promises made two years ago when executives accepted taxpayer subsidies in exchange for providing good-paying jobs.
Workers have been talking with the company since July 25, 2011, seeking guarantees that the company won’t get rid of good-paying jobs after getting a taxpayer bailout. Community concerns increased this spring when Bayer announced it was closing a nearby plant in Emeryville because they were outsourcing 400 jobs to a lower-cost facility overseas.
“It’s wrong for companies to take subsidies, promise good jobs to the community, then outsource those jobs after they’ve taken so much from taxpayers,” said Donal Mahon, a former Bayer veteran employee who is now helping workers negotiate a contract to protect good jobs and secure safer staffing levels at the Berkeley plant.
Bayer reported profits of nearly $2 billion dollars last year, based in part on $1.35 billion in sales of the drug Kogenate, which is manufactured in Berkeley.
“It just seems like Bayer and so many other companies are trying to take advantage of workers and communities during the recession,” said Mahon. “We’re trying to hold them accountable on behalf of everyone in the community who depends on good jobs in this area.”
If Bayer refuses to offer any job protection, workers state that they will evaluate a range of options aimed at encouraging the company to be more accountable to the community.
Northwest Analytics Launches Next Generation Enterprise Manufacturing Intelligence SolutionFrom Northwest Analytics
NWA Focus EMI Delivers Real Time Process Intelligence and Unique Accelerating Modules - a Shared Knowledge Base and Manufacturing-Centric Collaboration
Innovative Clinical Development Partnership Announced By Quintiles and Merck SeronoFrom MarketWatch.com
Agreement creates unique strategic collaboration for development and clinical trial execution
$15 Billion Myland Offer Rejected By ActavisFrom Bloomberg.com
Actavis has rejected drugmaker Mylan Inc's cash-and-stock offer for $15 billion. They have decided to continue talks to take over Warner Chilcott Plc instead, sources have said.
Rapid Micro Biosystems Offers Workshops at New European Headquarters in MunichFrom Rapid Micro Biosystems
Company hosts hands-on demonstrations of its Growth Direct System
Amgen, Zhejiang Beta Pharma Form Joint VentureFrom FOX Business
Amgen will form a joint venture with Chinese pharma firm to bring its colon cancer drug Vectibix to the Chinese market
Academic Tech Transfer Collaboration Required for Pharma R&D ModelFrom IT News Online
Pharma R&D Model Needs Academic Tech Transfer Collaboration for the Future of Drug Innovation Says New Report
CEM Wins Solid-Phase Peptide Synthesis Patent DisputeFrom CEM
CEM's European Patent covering microwave assisted solid phase peptide synthesis has been upheld in an oral proceeding
Biosimilars Market Prediction Up 20 Percent from 2012From Drug Store News
New report forecasts global $2.445 billion market this year
Cholesterol Drugs Could Help Kidney Cancer SurvivalFrom HealthDay News
Study finds statin medications tied to lower death risk after nearly four years of follow-up
Thermo Fisher Scientific Launches Online Configuration ToolFrom Thermo Fisher Scientific
iAutomate software reduces time needed for optimal system set-up design and provides accurate estimates
- All news »